Scientists Map 4300 Hidden Microproteins in Alzheimer Brain
The Blind Spot in Protein Detection
For decades, the standard way to identify which proteins a cell makes has been mass spectrometry. [1] This technique sorts molecules by weight and charge, and it works well for proteins of ordinary size. But it has a blind spot. Proteins shorter than 150 amino acids — called microproteins — are simply too small for the method to reliably catch. The foundational assumption that our catalogues of brain proteins were more or less complete rested on that blind spot being unimportant. It was not.
Researchers have now detected more than 1,000 previously overlooked microproteins in samples of human brain tissue, according to findings published in Nature Aging. [2] The work appeared in Nature Aging. The scale of the discovery forces a rethinking: if standard tools missed a thousand of these molecules in one brain region, what else has been invisible?
The team did not rely on mass spectrometry alone. They combined several methods to pinpoint the tiny molecules in postmortem samples of the dorsolateral prefrontal cortex — a region of the brain involved in cognitive control — taken from people with and without Alzheimer’s disease. In total, they identified more than 4,300 microproteins, creating the largest atlas of microproteins in Alzheimer’s disease assembled so far. That number matters because it converts a scattered set of anecdotal observations into a searchable map.
Brendan Miller, a neuroscientist at the Salk Institute for Biological Studies in San Diego, California, and a co-author of the study, framed the stakes plainly. [2] Alzheimer’s disease is a proteinopathy, he noted — a condition in which the pathology is in part due to proteins that have misfolded or accumulated and evoked a toxic response. “It should be somewhat urgent to understand the full proteome,” including microproteins, he said. [2] A proteome with a thousand missing entries is not full.
Separate Labs, Same Blind Spot
The difficulty of finding microproteins is not incidental — it is structural. Because of their short length, mass spectrometry often fails to detect them, which is why they are sometimes referred to as “the dark matter of the genome,” as Miller put it. Some microproteins are made by parts of the genome that were thought to be non-coding and unable to produce proteins at all. Others are made from coding genes that also produce large, known proteins. That second category is what breaks conventional RNA sequencing: the same gene yields both a familiar large protein and a tiny hidden one, so standard techniques cannot tell them apart.
Bahareh Ajami, a neuroimmunologist at Cedars-Sinai Medical Center in Los Angeles, California, drew the broader conclusion. [3] “We might be actually missing a whole layer of biology by overlooking these microproteins,” she said. [3] That is not a rounding error or a footnote; it is a statement that redirects a field.
The finding that dozens of these tiny proteins showed altered expression in people with Alzheimer’s disease is what turns the atlas from a catalogue into a lead. If microproteins change in the disease, they may point toward mechanisms of ageing and neurodegeneration that were never on the table before. The same question — what does the brain’s protein landscape actually contain? — is being pursued by independent groups that reached the same conclusion: the conventional map was incomplete.
How Far the Map Reaches
The atlas is built from postmortem tissue of a single brain region, the dorsolateral prefrontal cortex. That is a real constraint. The dorsolateral prefrontal cortex is involved in cognitive control, but it is not the whole brain, and Alzheimer’s disease does not confine itself to one area. A map of one neighborhood is not a map of the city.
The samples came from people with and without Alzheimer’s disease, which allows comparison, but comparison of postmortem tissue captures an end state, not the progression that produced it. Whether the altered microprotein expression drives the disease, results from it, or merely accompanies it cannot be settled by this dataset. The study identifies candidates; it does not assign roles.
Detection itself remains the bottleneck. The team needed several combined methods to find these molecules precisely because no single standard technique could do the job. Until microprotein detection becomes routine rather than a research feat, every new atlas will be built the hard way, one region at a time. The thousand overlooked proteins are now visible. How many remain overlooked elsewhere is exactly as open as it was before.
Sources
1. DOI: 10.1038/d41586-026-02914-6